Skip to main
MGTX

MGTX Stock Forecast & Price Target

MGTX Analyst Ratings

Based on 7 analyst ratings
Strong Buy
Strong Buy 57%
Buy 43%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

MeiraGTx Holdings is a company with a strong pipeline of targeted therapies for high unmet need diseases, backed by in-house manufacturing capabilities and proprietary platforms to enhance efficacy and reduce dosage. The company also has a diverse and inclusive workforce, with a focus on sustainability and alignment with sustainable finance principles. The company's partnerships, including a recent deal with a private AI healthcare company, provide additional financing opportunities, and its rare inherited retinal disease program could also offer non-dilutive financing. Recent financials showed a beat on net income driven by one-time revenue recognition and the company expects a positive outcome from its pivotal xerostomia Phase II study in 2027. The company's focus on disease-modifying treatments, a robust clinical pipeline, and potential for near-term milestones make it a promising investment opportunity, although risks include clinical execution, regulatory uncertainties, and competition.

Bears say

MeiraGTx Holdings is a clinical-stage genetic medicines company that is facing several fundamental challenges, including a high-risk pipeline, limited revenue growth opportunities, and significant upfront costs for gene therapy trials and manufacturing capabilities. The company also has a limited track record of successful clinical trials and is heavily reliant on milestone payments and non-dilutive financing, which may not be sustainable in the long term. Additionally, MeiraGTx's small market opportunities and competitive landscape in inherited retinal diseases may ultimately impact its revenue potential. Overall, these factors contribute to our negative outlook on the company's stock.

MGTX has been analyzed by 7 analysts, with a consensus rating of Strong Buy. 57% of analysts recommend a Strong Buy, 43% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of MeiraGTx Holdings plc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About MeiraGTx Holdings plc (MGTX) Forecast

Analysts have given MGTX a Strong Buy based on their latest research and market trends.

According to 7 analysts, MGTX has a Strong Buy consensus rating as of Aug 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

MeiraGTx Holdings plc (MGTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.